FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
404 letters match. Newest first.
-
Drugsonlineotcmeds.com
FDA warned onlineotcmeds.com for selling unapproved, misbranded opioids, benzodiazepines, and Schedule II stimulants to U.S. consumers online.
High risk -
Drugswww.usmedschoice.com
FDA warned www.usmedschoice.com for selling unapproved and misbranded opioids, benzodiazepines, and stimulants online without prescriptions.
High risk -
Drugsmotionpharmacy.com
FDA warns motionpharmacy.com over selling unapproved and misbranded prescription drugs online.
High risk -
Drugscheaptrustedpharmacy.com
cheaptrustedpharmacy.com sells unapproved, misbranded prescription drugs to U.S. consumers online, FDA warns.
High risk -
DrugsGet.Fit.Medical, LLC dba Get.Fit.Medical
FDA warned Get.Fit.Medical that its website sold compounded sildenafil, tadalafil, semaglutide and tirzepatide with false 'generic' claims.
High risk -
DrugsFWD Care, Inc. dba FWD
FDA warned telehealth company FWD Care that its website claims for compounded semaglutide and tirzepatide drugs are false or misleading.
Medium -
DrugsExpert Aesthetics
FDA warned Expert Aesthetics over website claims that its compounded semaglutide and tirzepatide are generic Ozempic and Mounjaro.
Low -
DrugsDermacare LLC dba BlueChew
FDA warned BlueChew over website claims that its compounded sildenafil and tadalafil are the same as Viagra and Cialis.
High risk -
DrugsHealthy Living Clinic
FDA warned Healthy Living Clinic that its website misbrands compounded semaglutide by comparing it to Wegovy, Ozempic, and Rybelsus.
Low -
DrugsHims & Hers Health, Inc. dba Hers
FDA warned Hims & Hers (Hers) that its website misleads consumers about compounded semaglutide by implying it is the same as approved Ozempic and Wegovy.
Medium -
DrugsAmazing Meds
FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.
High risk -
DrugsGenLabMeds
GenLabMeds offered compounded retatrutide, semaglutide and tirzepatide online as unapproved, misbranded drugs with false or misleading claims.
High risk -
DrugsFitRX, LLC dba Zealthy
FDA warns Zealthy over website claims that compounded semaglutide is the same as Wegovy and Ozempic.
Medium -
DrugsLean Dreams LLC dba LeanDreams
FDA warned LeanDreams over website claims that compounded semaglutide and tirzepatide match FDA-approved Ozempic, Wegovy, Mounjaro and Zepbound.
Low -
Drugsybycmeds
FDA warns ybycmeds over website claims that compounded semaglutide and tirzepatide are similar to approved brand-name drugs.
Medium -
DrugsiVisitDoc, Inc. dba iVisitDoc
FDA warns iVisitDoc over website claims that compounded semaglutide is equivalent to Wegovy and Ozempic, calling the drugs misbranded.
Medium -
DrugsTry Nova
FDA warned Try Nova that its website’s compounded semaglutide claim "Same active ingredient as Wegovy & Ozempic" is false or misleading.
Low -
DrugsLovely Meds, Inc. dba Lovely Meds
FDA cited Lovely Meds for misleading website claims that compounded semaglutide and tirzepatide are the same as FDA-approved drugs.
Low -
DrugsThe HCG Institute
FDA warns The HCG Institute over misleading claims for compounded semaglutide sold online.
High risk -
DrugsVitals RX
FDA warned telehealth seller Vitals RX that its website falsely implies compounded semaglutide and tirzepatide are the approved drug Ozempic.
Medium -
DrugsTuyo Health, Inc. dba Tuyo Health
FDA warns Tuyo Health over misleading claims for compounded semaglutide and tirzepatide sold online.
Medium -
DrugsLas Villas Health Care LLC dba Villas Health
FDA warned Villas Health over website claims for compounded semaglutide and sildenafil, calling the drugs misbranded and unapproved.
High risk -
DrugsLyfe Rx
Lyfe Rx offered compounded semaglutide and tirzepatide online with false 'clinically proven weight loss' claims, FDA says.
Low -
DrugsJulyMD
FDA warned JulyMD that its website sold compounded semaglutide with misleading claims comparing it to Wegovy and Ozempic.
High risk -
DrugsSlendid
FDA warned Slendid that its website sells compounded semaglutide and tirzepatide with a false "clinically proven" claim, making the drugs misbranded.
Medium -
DrugsHello Cake, Inc. dba Hello Cake
FDA warns Hello Cake, an online telehealth seller, that its website misbrands compounded sildenafil and tadalafil ED drugs as equivalent to Viagra and Cialis.
Medium -
DrugsBiopreventative Company LLC dba Biopreventative
FDA told Biopreventative its website claim that compounded tadalafil is "commonly known as Cialis" misbrands the drug.
Low -
DrugsSprout Health Partners LLC dba Sprout Health
FDA warned telehealth seller Sprout Health that its website's claim compounded semaglutide and tirzepatide are FDA-approved makes the drugs misbranded.
Low -
DrugsMaster Pharmaceuticals Group
FDA warned Master Pharmaceuticals Group that its website sold compounded semaglutide and tirzepatide with false or misleading claims.
High risk -
DrugsTRYM Health, Inc. dba TRYM Health
FDA told telehealth seller TRYM Health its website claims for compounded semaglutide and tirzepatide are false and misleading, making the drugs misbranded.
Medium -
DrugsHealBerry
FDA warned HealBerry that claiming compounded semaglutide has the 'same active ingredient as Ozempic and Wegovy' misbrands its drugs.
Medium -
DrugsReset IV, LLC dba Reset IV
FDA warned Reset IV that its website misbrands compounded semaglutide and tirzepatide by claiming they are the same as FDA-approved drugs.
Medium -
Drugsinspire.clinic
FDA warned telehealth site inspire.clinic that claims its compounded semaglutide and tirzepatide are similar to Ozempic or Mounjaro misbrand the drugs.
Low -
DrugsBioverse, Inc. dba Bioverse
FDA warned Bioverse that its website made false or misleading claims for compounded semaglutide and tirzepatide drugs.
Low -
DrugsSimpleRx
FDA warned SimpleRx that its website falsely implied compounded semaglutide and tirzepatide were Ozempic or Zepbound.
High risk -
DrugsElevate Your Wellness LLC, dba Elevated
FDA warned Elevated that its website offered compounded semaglutide and tirzepatide with misleading claims they match FDA-approved drugs.
Low -
DrugsCosmo Medical Spa dba Cosmo Med Spa
FDA warned Cosmo Med Spa over its website selling compounded semaglutide with claims implying it is FDA-approved Ozempic.
Medium -
DrugsEvoLife Wellness
FDA warned EvoLife Wellness that its website wrongly calls compounded semaglutide and tirzepatide "FDA-Approved," making the drugs misbranded.
Medium -
DrugseDrugstore
FDA warns eDrugstore over claims that compounded tirzepatide is FDA-approved, making drugs misbranded (falsely promoted).
High risk -
DrugsNuvo Life Health Inc. dba Nuvo Life Health
FDA warned Nuvo Life Health that its website sold compounded semaglutide and tirzepatide with misleading claims comparing them to FDA-approved drugs.
Medium -
DrugsSemaBio
FDA warned SemaBio that its website sold compounded semaglutide and called it 'generic semaglutide,' a false or misleading claim.
Low -
Drugsdirectmeds.com, Inc. dba DirectMeds
FDA warned DirectMeds that its website sold compounded semaglutide and tirzepatide with false or misleading claims implying they match FDA-approved drugs.
High risk -
DrugsHims & Hers Health, Inc. dba Hims
FDA warns Hims that compounded semaglutide website claims are false or misleading and misbrand the drugs.
High risk -
DrugsMedClub by Dr. Jenn
FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.
High risk -
DrugsMane & Steel, LLC. dba Mane & Steel
FDA warns Mane & Steel over false 'clinically proven' claims for compounded semaglutide.
Low -
DrugsLumimeds
FDA warns Lumimeds over website claims implying its compounded semaglutide and tirzepatide are FDA-approved.
High risk -
DrugsGLP-1 Solution
GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.
High risk -
DrugsASN-LABS
ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.
High risk -
DrugsBody Good Studio
FDA warned Body Good Studio over its website selling compounded semaglutide with a false claim that it matches Ozempic and Wegovy.
High risk -
DrugsCanada Med Stop
Canada Med Stop marketed compounded semaglutide online as FDA-approved and generic, making the drugs misbranded.
Medium